Abstract

AbstractBackgroundAs the cerebral cortex is an important indicator of the pathological changes of AD, ApoB, ApoA1, ApoB/ApoA1 and blood Alzheimer’s biomarkers have been proved to be important markers of AD.MethodWe analyzed data from 21 patients with SCD enrolled in the 500 nm light therapy cohort who filled a battery of neuropsychological tests and had apolipoproteins, plasma Alzheimer’s biomarkers, and gene levels assessed at the time of their baseline 3T MRI scans. The sulcal depth and cortical thickness were obtained using the vertex‐based approach with the CAT12 toolbox (in SPM12).ResultAt corrected thresholds (p < 0.05, FWE‐corrected), there were significant positive correlations between ApoB and sulcal depth in the lateral occipital cortex, and between ApoB/ApoA1 and sulcal depth in the left lateral occipital cortex. In addition, we found a significant negative correlation between shape trails test part B (STT‐B) time and sulcal depth in the left lateral occipital cortex (β = ‐0.502, p = 0.040). Moreover, the plasma Aβ42 was positively related to sulcal depth (β = 0.493, p = 0.044) and plasma p‐tau181 was negatively related to the sulcal depth (β = ‐0.592, p = 0.012) in the left lateral occipital cortex. There was no relationship between cortical thickness and apolipoproteins or any of the biomarkers.ConclusionApoB and ApoB/ApoA1 influence sulcal depth in the left lateral occipital cortex where the sulcal depth may relate to the executive function and plasma Alzheimer’s biomarkers in SCD.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call